Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 11/20 | 0.41 |
| ▸ | CPT2 | P23786 | 6/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | PRCP | P42785 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15310072 | 0.91 | KMT2A (0.43) | CPT1ACPT2FFAR1MEN1KMT2A | |
| SCHEMBL2223318 | 0.90 | CPT1A (0.41) | CPT1ACPT2FFAR1S1PR1PRCP | |
| SCHEMBL15309978 | 0.88 | HPGD (0.41) | CPT1APDK2MEN1KMT2AS1PR1 | |
| SCHEMBL15310017 | 0.86 | CPT1A (0.38) | CPT1ACPT2FFAR1MEN1KMT2A | |
| SCHEMBL2224649 | 0.85 | S1PR1 (0.51) | CPT1ACPT2FFAR1S1PR1PRCP | |
| SCHEMBL15309861 | 0.84 | POLB (0.42) | CPT1AMEN1KMT2A | |
| SCHEMBL2223289 | 0.84 | S1PR1 (0.42) | CPT1ACPT2S1PR1PRCP | |
| SCHEMBL15310209 | 0.83 | S1PR1 (0.39) | CPT1ACPT2S1PR1 | |
| SCHEMBL2223315 | 0.82 | GYS1 (0.44) | CPT1ACPT2KMT2A | |
| SCHEMBL14777269 | 0.82 | GYS1 (0.44) | CPT1ACPT2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2523960-B1 | HETEROCYCLIC CARBOXYLIC ACID DERIVATIVES HAVING A 2,5-SUBSTITUTED OXAZOLOPYRIMIDINE RING | SANOFI SA (FR) | 2013-10-16 | — | — | EP | disclosed |